Mitochondrial Ca2+ and membrane potential, an alternative pathway for Interleukin 6 to regulate CD4 cell effector function

  1. Rui Yang
  2. Dario Lirussi
  3. Tina M Thornton
  4. Dawn M Jelley-Gibbs
  5. Sean A Diehl
  6. Laure K Case
  7. Muniswamy Madesh
  8. Douglas J Taatjes
  9. Cory Teuscher
  10. Laura Haynes
  11. Mercedes Rincón  Is a corresponding author
  1. University of Vermont, United States
  2. Helmholtz Center for Infection Research, Germany
  3. Taconic, United States
  4. Temple University, United States
  5. Trudeau Institute, United States

Abstract

IL-6 plays an important role in determining the fate of effector CD4 cells and the cytokines that these cells produce. Here we identify a novel molecular mechanism by which IL-6 regulates CD4 cell effector function. We show that IL-6-dependent signal facilitates the formation of mitochondrial respiratory chain supercomplexes to sustain high mitochondrial membrane potential late during activation of CD4 cells. Mitochondrial hyperpolarization caused by IL-6 is uncoupled from the production of ATP by oxidative phosphorylation. However, it is a mechanism to raise the levels of mitochondrial Ca2+ late during activation of CD4 cells. Increased levels of mitochondrial Ca2+ in the presence of IL-6 are used to prolong Il4 and Il21 expression in effector CD4 cells. Thus, the effect of IL-6 on mitochondrial membrane potential and mitochondrial Ca2+ is an alternative pathway by which IL-6 regulates effector function of CD4 cells and it could contribute to the pathogenesis of inflammatory diseases.

Article and author information

Author details

  1. Rui Yang

    Department of Medicine, Immunobiology Program, University of Vermont, Burlington, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Dario Lirussi

    Department of Vaccinology and Applied Microbiology, Helmholtz Center for Infection Research, Braunschweig, Germany
    Competing interests
    The authors declare that no competing interests exist.
  3. Tina M Thornton

    Department of Medicine, Immunobiology Program, University of Vermont, Burlington, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Dawn M Jelley-Gibbs

    Taconic, Germantown, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Sean A Diehl

    Department of Medicine, Immunobiology Program, University of Vermont, Burlington, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Laure K Case

    Department of Medicine, Immunobiology Program, University of Vermont, Burlington, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Muniswamy Madesh

    Department of Medical Genetics and Molecular Biochemistry, Temple University, Philadelphia, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Douglas J Taatjes

    Department of Pathology and Laboratory Medicine, University of Vermont, Burlington, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Cory Teuscher

    Department of Medicine, Immunobiology Program, University of Vermont, Burlington, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Laura Haynes

    Trudeau Institute, Saranac lake, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Mercedes Rincón

    Department of Medicine, Immunobiology Program, University of Vermont, Burlington, United States
    For correspondence
    mrincon@uvm.edu
    Competing interests
    The authors declare that no competing interests exist.

Ethics

Animal experimentation: All procedures performed on the mice were approved by the Institutional Animal Care and Use Committee (IACUC) of University of Vermont using protocols #12-032 (Rincon), #11-024 (Teuscher) and by the IACUC of Trudeau Institute using protocol #03-005 (Haynes).

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 5,564
    views
  • 1,029
    downloads
  • 71
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Rui Yang
  2. Dario Lirussi
  3. Tina M Thornton
  4. Dawn M Jelley-Gibbs
  5. Sean A Diehl
  6. Laure K Case
  7. Muniswamy Madesh
  8. Douglas J Taatjes
  9. Cory Teuscher
  10. Laura Haynes
  11. Mercedes Rincón
(2015)
Mitochondrial Ca2+ and membrane potential, an alternative pathway for Interleukin 6 to regulate CD4 cell effector function
eLife 4:e06376.
https://doi.org/10.7554/eLife.06376

Share this article

https://doi.org/10.7554/eLife.06376

Further reading

    1. Immunology and Inflammation
    Yan Qian, Qiannv Liu ... Pengyan Xia
    Research Article

    The T6SS of Pseudomonas aeruginosa plays an essential role in the establishment of chronic infections. Inflammasome-mediated inflammatory cytokines are crucial for host defense against bacterial infections. We found that P. aeruginosa infection activates the non-canonical inflammasome in macrophages, yet it inhibits the downstream activation of the NLRP3 inflammasome. The VgrG2b of P. aeruginosa is recognized and cleaved by caspase-11, generating a free C-terminal fragment. The VgrG2b C-terminus can bind to NLRP3, inhibiting the activation of the NLRP3 inflammasome by rejecting NEK7 binding to NLRP3. Administration of a specific peptide that inhibits caspase-11 cleavage of VgrG2b significantly improves mouse survival during infection. Our discovery elucidates a mechanism by which P. aeruginosa inhibits host immune response, providing a new approach for the future clinical treatment of P. aeruginosa infections.

    1. Immunology and Inflammation
    2. Medicine
    Ole Bæk, Tik Muk ... Duc Ninh Nguyen
    Research Article

    Preterm infants are susceptible to neonatal sepsis, a syndrome of pro-inflammatory activity, organ damage, and altered metabolism following infection. Given the unique metabolic challenges and poor glucose regulatory capacity of preterm infants, their glucose intake during infection may have a high impact on the degree of metabolism dysregulation and organ damage. Using a preterm pig model of neonatal sepsis, we previously showed that a drastic restriction in glucose supply during infection protects against sepsis via suppression of glycolysis-induced inflammation, but results in severe hypoglycemia. Now we explored clinically relevant options for reducing glucose intake to decrease sepsis risk, without causing hypoglycemia and further explore the involvement of the liver in these protective effects. We found that a reduced glucose regime during infection increased survival via reduced pro-inflammatory response, while maintaining normoglycemia. Mechanistically, this intervention enhanced hepatic oxidative phosphorylation and possibly gluconeogenesis, and dampened both circulating and hepatic inflammation. However, switching from a high to a reduced glucose supply after the debut of clinical symptoms did not prevent sepsis, suggesting metabolic conditions at the start of infection are key in driving the outcome. Finally, an early therapy with purified human inter-alpha inhibitor protein, a liver-derived anti-inflammatory protein, partially reversed the effects of low parenteral glucose provision, likely by inhibiting neutrophil functions that mediate pathogen clearance. Our findings suggest a clinically relevant regime of reduced glucose supply for infected preterm infants could prevent or delay the development of sepsis in vulnerable neonates.